---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-025571"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-07-26T23:59:59+00:00"
generated_at: "2026-06-13T02:18:35.049609+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma enters $5M equity line with Dutchess Capital at 85% discount

## Summary
- Up to $5M of common stock sales over 24 months; purchase price 85% of lowest trading price during 7-day pricing period.
- Maximum drawdown per notice: the lesser of $200,000 or 200% of 5-day average daily trading value; minimum $5,000 per notice.
- Per drawdown, cannot exceed 52.5M shares or cause investor ownership above 4.99% of outstanding shares.
- Proceeds used for R&D, clinical study manufacturing, working capital, and general corporate purposes.
- Registration statement must be effective before any drawdown; registration rights agreement requires filing within 45 days.

## SEC filing metadata
- accession: 0001493152-23-025571
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-07-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223025571/0001493152-23-025571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223025571/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-025571
- JSON: https://secwatch.observer/filing/0001493152-23-025571.json
- Plain text: https://secwatch.observer/filing/0001493152-23-025571.txt

## Key facts
- Material Agreements
  Propanc Biopharma, Inc. entered into common stock purchase agreement with an institutional investor valued at up to $5,000,000 (effective 2023-07-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an institutional investor
  - Value: up to $5,000,000
  - Effective: 2023-07-20
  source text: On July 20, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a common stock purchase agreement (the “Equity Line Agreement”) with an institutional investor (the “Investor”) providing for an equity financing facility, pursuant to which Company has the option to request that the Investor commit to purchase up to $5,000,000 of the Company’s shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223025571/0001493152-23-025571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.